Brief: Hyloris Submits Maxigesic IV Packaging Data Requested By FDA

Hyloris Pharmaceuticals SA

18/04/2023 06:11

April 18 (Reuters) - Hyloris Pharmaceuticals SA
 HYL.BR :
    * REG-HYLORIS ANNOUNCES SUBMISSION OF MAXIGESIC® IV
PACKAGING DATA
REQUESTED BY THE US FDA
    * RESULTS ANALYZED AND EVALUATED BY TOXICOLOGICAL EXPERTS
    * POTENTIAL REGULATORY APPROVAL FOR MAXIGESIC® IV FOR THE US
MARKET BEFORE THE END OF 2023
    * POTENTIAL REGULATORY APPROVAL FOR MAXIGESIC® IV FOR US
MARKET
BEFORE END OF 2023
    * SALES COULD FOLLOW SOON AFTER, WITH AN EXCLUSIVE LICENSE
AND
DISTRIBUTION AGREEMENT ALREADY SIGNED BETWEEN AFT AND HIKMA
PHARMACEUTICALS ("HIKMA")
    * UNDER TERMS OF DEVELOPMENT COLLABORATION AGREEMENT BETWEEN
HYLORIS AND AFT, HYLORIS IS ELIGIBLE TO RECEIVE A SHARE ON ANY
PRODUCT-RELATED REVENUES

Source text for Eikon:  ID:nGNEmD1tp 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))